J Reconstr Microsurg 2022; 38(02): 137-143
DOI: 10.1055/s-0041-1731640
Original Article

Long-Term Opioid Use Following Surgery for Symptomatic Neuroma

Jonathan Lans
1   Department of Orthopaedic Surgery, Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston
,
Ritsaart F. Westenberg
1   Department of Orthopaedic Surgery, Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston
,
Rachel E. Gottlieb
1   Department of Orthopaedic Surgery, Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston
,
Ian L. Valerio
2   Division of Plastic Surgery, Hand Surgery, and Peripheral Nerve Surgery, Massachusetts General Hospital, Harvard Medical School, Boston
,
Neal C. Chen
1   Department of Orthopaedic Surgery, Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston
,
Kyle R. Eberlin
2   Division of Plastic Surgery, Hand Surgery, and Peripheral Nerve Surgery, Massachusetts General Hospital, Harvard Medical School, Boston
› Institutsangaben
Funding None.

Abstract

Background Identifying patients at risk for prolonged opioid use following surgery for symptomatic neuroma would be beneficial for perioperative management. The aim of this study is to identify the factors associated with postoperative opioid use of >4 weeks in patients undergoing neuroma surgery.

Methods After retrospective identification, 77 patients who underwent surgery for symptomatic neuroma of the upper or lower extremity were enrolled. Patients completed the Patient-Reported Outcomes Measurement Information System (PROMIS) depression, Numeric Rating Scale (NRS) pain score, and a custom medication questionnaire at a median of 9.7 years (range: 2.5–16.8 years) following surgery. Neuroma excision followed by nerve implantation (n = 39, 51%), nerve reconstruction/repair (n = 18, 23%), and excision alone (n = 16, 21%) were the most common surgical treatments.

Results Overall, 27% (n = 21) of patients reported opioid use of more than 4 weeks postoperatively. Twenty-three patients (30%) reported preoperative opioid use of which 11 (48%) did not report opioid use for >4 weeks, postoperatively. In multivariable logistic regression, preoperative opioid use was independently associated with opioid use of >4 weeks, postoperatively (odds ratio [OR] = 4.4, 95% confidence interval [CI]: 1.36–14.3, p = 0.013).

Conclusion Neuroma surgery reduces opioid use in many patients but patients who are taking opioids preoperatively are at risk for longer opioid use. Almost one-third of patients reported opioid use longer than 4 weeks, postoperatively.

Financial Disclosure Statement

R.F.W. and I.L.V. have nothing to disclose. J.L. is a consultant for AxoGen. N.C.C. is consultant for Flexion Medical, Miami Device Solutions, and a lecturer for DePuy Synthes. K.R.E is a consultant for AxoGen, Checkpoint and Integra. No funding was received for this article.


Authors' Contributions

Study design: J.L., R.F.W., N.C.C., and K.R.E.


Data assembly: J.L., R.F.W., and R.E.G.


Data analysis: J.L., R.F.W., N.C.C., and K.R.E.


Initial draft: J.L., R.F.W., I.L.V., N.C.C., and K.R.E.


Final approval of manuscript: J.L., R.F.W., R.E.G., I.L.V., N.C.C., and K.R.E.


Supplementary Material



Publikationsverlauf

Eingereicht: 06. Januar 2021

Angenommen: 12. Mai 2021

Artikel online veröffentlicht:
16. Juli 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Lans J, Hoftiezer Y, Lozano-Calderón SA, Heng M, Valerio IL, Eberlin KR. Risk factors for neuropathic pain following major upper extremity amputation. J Reconstr Microsurg 2021; 37 (05) 413-420
  • 2 Domeshek LF, Krauss EM, Snyder-Warwick AK. et al. Surgical treatment of neuromas improves patient-reported pain, depression, and quality of life. Plast Reconstr Surg 2017; 139 (02) 407-418
  • 3 Stokvis A, van der Avoort DJC, van Neck JW, Hovius SER, Coert HJ. Surgical management of neuroma pain: a prospective follow-up study. Pain 2010; 151 (03) 862-869
  • 4 Poppler LH, Parikh RP, Bichanich MJ. et al. Surgical interventions for the treatment of painful neuroma: a comparative meta-analysis. Pain 2018; 159 (02) 214-223
  • 5 McNamara CT, Iorio ML. Targeted muscle reinnervation: outcomes in treating chronic pain secondary to extremity amputation and phantom limb syndrome. J Reconstr Microsurg 2020; 36 (04) 235-240
  • 6 Stokvis A, Coert JH, van Neck JW. Insufficient pain relief after surgical neuroma treatment: prognostic factors and central sensitisation. J Plast Reconstr Aesthet Surg 2010; 63 (09) 1538-1543
  • 7 Helmerhorst GTT, Vranceanu AM, Vrahas M, Smith M, Ring D. Risk factors for continued opioid use one to two months after surgery for musculoskeletal trauma. J Bone Jt Surg - Ser A 2014; 96 (06) 495-499
  • 8 Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016; 65 (50,51): 1445-1452
  • 9 Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief 2014; (166) 1-8
  • 10 Paulozzi L, Jones C, Mack K, Rudd R. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. Morb Mortal Wkly Rep 2011; 60 (43) 1487-1492
  • 11 Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care 2016; 54 (10) 901-906
  • 12 Larach DB, Sahara MJ, As-Sanie S. et al. Patient factors associated with opioid consumption in the month following major surgery. Ann Surg 2019; 273 (03) 507-515
  • 13 Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg 2017; 125 (05) 1741-1748
  • 14 Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. JAMA Intern Med 2016; 176 (09) 1286-1293
  • 15 Reid DBC, Shah KN, Shapiro BH, Ruddell JH, Akelman E, Daniels AH. Mandatory prescription limits and opioid utilization following orthopaedic surgery. J Bone Joint Surg Am 2019; 101 (10) e43
  • 16 Moura S, Nicholson S, Hoftiezer Y, Lans J, Chen N, Eberlin K. Defining Prolonged Opioid Use After Surgery – A Systematic Review and Proposed Criteria for Hand Surgery. Submitted for publication to HAND
  • 17 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
  • 18 Kim J, Lonner JH, Nelson CL, Lotke PA. Response bias: effect on outcomes evaluation by mail surveys after total knee arthroplasty. J Bone Jt Surg - Ser A 2004; 86 (01) 15-21
  • 19 Westenberg RF, Nierich J, Lans J, Garg R, Eberlin KR, Chen NC. What factors are associated with response rates for long-term follow-up questionnaire studies in hand surgery?. Clin Orthop Relat Res 2020; 478 (12) 2889-2898
  • 20 Ciesielski T, Iyengar R, Bothra A, Tomala D, Cislo G, Gage BF. A tool to assess risk of de novo opioid abuse or dependence. Am J Med 2016; 129 (07) 699-705.e4
  • 21 Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2017. NCHS Data Brief 2018; 329 (329) 1-8
  • 22 Guy Jr GP, Zhang K, Bohm MK. et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. Morb Mortal Wkly Rep 2017; 66 (26) 697-704
  • 23 Young JD, Bhashyam AR, Qudsi RA. et al. Cross-cultural comparison of postoperative discharge opioid prescribing after orthopaedic trauma surgery. J Bone Joint Surg Am 2019; 101 (14) 1286-1293
  • 24 Bhashyam AR, Keyser C, Miller CP. et al. Prospective evaluation of opioid use after adoption of a prescribing guideline for outpatient foot and ankle surgery. Foot Ankle Int 2019; 40 (11) 1260-1266
  • 25 Kvarda P, Hagemeijer NC, Waryasz G, Guss D, DiGiovanni CW, Johnson AH. Opioid consumption rate following foot and ankle surgery. Foot Ankle Int 2019; 40 (08) 905-913
  • 26 Dwyer CL, Soong M, Hunter A, Dashe J, Tolo E, Kasparyan NG. Prospective evaluation of an opioid reduction protocol in hand surgery. J Hand Surg Am 2018; 43 (06) 516-522.e1
  • 27 Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg 2017; 152 (11) 1066-1071
  • 28 Chua KP, Brummett CM, Waljee JF. Opioid prescribing limits for acute pain: potential problems with design and implementation. JAMA 2019; 321 (07) 643-644
  • 29 Howard R, Waljee J, Brummett C, Englesbe M, Lee J. Reduction in opioid prescribing through evidence-based prescribing guidelines. JAMA Surg 2018; 153 (03) 285-287
  • 30 Stewart TM, Pulos N, Curry TB, Gazelka HM, Brown MJ, Shin AY. Team approach: multimodal perioperative pain management in upper-extremity surgery: combating the opioid epidemic. JBJS Rev 2018; 6 (08) e5
  • 31 Khazi ZM, Lu Y, Shamrock AG, Duchman KR, Westermann RW, Wolf BR. Opioid use following shoulder stabilization surgery: risk factors for prolonged use. J Shoulder Elbow Surg 2019; 28 (10) 1928-1935
  • 32 Dy CJ, Peacock K, Olsen MA, Ray WZ, Brogan DM. Frequency and risk factors for prolonged opioid prescriptions after surgery for brachial plexus injury. J Hand Surg Am 2019; 44 (08) 662-668.e1
  • 33 Lans J, Baker DJ, Castelein RM, Sood RF, Chen NC, Eberlin KR. Patient-reported outcomes following surgical treatment of symptomatic digital neuromas. Plast Reconstr Surg 2020; 145 (03) 563e-573e
  • 34 Johnson SP, Chung KC, Zhong L. et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. J Hand Surg Am 2016; 41 (10) 947-957.e3
  • 35 Clarke H, Soneji N, Ko DT, Yun L, Wijeysundera DN. Rates and risk factors for prolonged opioid use after major surgery: population based cohort study. BMJ 2014; 348: g1251
  • 36 Scully RE, Schoenfeld AJ, Jiang W. et al. Defining optimal length of opioid pain medication prescription after common surgical procedures. JAMA Surg 2018; 153 (01) 37-43
  • 37 Ilyas AM, Miller AJ, Graham JG, Matzon JL. Pain management after carpal tunnel release surgery: a prospective randomized double-blinded trial comparing acetaminophen, ibuprofen, and oxycodone. J Hand Surg Am 2018; 43 (10) 913-919
  • 38 Roeckel LA, Le Coz GM, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience 2016; 338: 160-182
  • 39 Morgan MM, Christie MJ. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 2011; 164 (04) 1322-1334
  • 40 Weinberger AH, Platt J, Esan H, Galea S, Erlich D, Goodwin RD. Cigarette smoking is associated with increased risk of substance use disorder relapse: a nationally representative, prospective longitudinal investigation Andrea. J Clin Psychiatry 2017; 78 (02) e152-e160
  • 41 Goodwin RD, Fergusson DM, Horwood LJ. Association between anxiety disorders and substance use disorders among young persons: results of a 21-year longitudinal study. J Psychiatr Res 2004; 38 (03) 295-304
  • 42 Jamal M, Willem Van der Does AJ, Cuijpers P, Penninx BWJH. Association of smoking and nicotine dependence with severity and course of symptoms in patients with depressive or anxiety disorder. Drug Alcohol Depend 2012; 126 (1,2): 138-146
  • 43 Siqueira L, Diab M, Bodian C, Rolnitzky L. Adolescents becoming smokers: the roles of stress and coping methods. J Adolesc Health 2000; 27 (06) 399-408
  • 44 Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014; 348: g1151
  • 45 Rao AG, Chan PH, Prentice HA, Paxton EW, Funahashi TT, Maletis GB. Risk factors for opioid use after anterior cruciate ligament reconstruction. Am J Sports Med 2019; 47 (09) 2130-2137
  • 46 Chapman T, Kim N, Maltenfort M, Ilyas AM. Prospective evaluation of opioid consumption following carpal tunnel release surgery. Hand (N Y) 2017; 12 (01) 39-42
  • 47 Bond C, LaForge KS, Tian M. et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95 (16) 9608-9613
  • 48 McNicol ED, Midbari A, Eisenberg E. Opiods for neuropathic pain. Cochrane Database Syst Rev 2015;
  • 49 Finnerup NB, Attal N, Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14 (02) 162-173
  • 50 Bates D, Schultheis BC, Hanes MC. et al. A comprehensive algorithm for management of neuropathic pain. Pain Med 2019; 20 (1, suppl 1): S2-S12
  • 51 Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352 (13) 1324-1334
  • 52 Gilron I, Tu D, Holden RR, Jackson AC, DuMerton-Shore D. Combination of morphine with nortriptyline for neuropathic pain. Pain 2015; 156 (08) 1440-1448
  • 53 Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012; 2012 (07) CD008943
  • 54 Gilron I, Biederman J, Jhamandas K, Hong M. Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests. Anesthesiology 2003; 98 (05) 1288-1292
  • 55 Hah J, Mackey SC, Schmidt P. et al. Effect of perioperative gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort a randomized clinical trial. JAMA Surg 2018; 153 (04) 303-311
  • 56 Han C, Li XD, Jiang HQ, Ma JX, Ma XL. The use of gabapentin in the management of postoperative pain after total hip arthroplasty: a meta-analysis of randomised controlled trials. J Orthop Surg Res 2016; 11 (01) 79
  • 57 Clarke H, Kirkham KR, Orser BA. et al. Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. Can J Anaesth 2013; 60 (05) 432-443